Using topiramate or naltrexone for the treatment of alcohol-dependent patients

Alcoholism: Clinical and Experimental Research

Volumn 32, Issue 7, 2008, Pages 1251-1259

  Flórez, Gerardo ^a   García Portilla, Paz ^b   Álvarez, Sandra ^a   Saiz, Pilar A ^b   Nogueiras, Luis ^a   Bobes, Julio ^b  

^a Unidad Asistencial As Burgas   (Spain)

^b UNIVERSITY OF OVIEDO   (Spain)

Author keywords

Alcohol; Craving; Naltrexone; Topiramate; Treatment

Indexed keywords

ALCOHOL; BIOLOGICAL MARKER; DISULFIRAM; NALTREXONE; TOPIRAMATE; DRUG DERIVATIVE; FRUCTOSE; NARCOTIC ANTAGONIST; NEUROPROTECTIVE AGENT;

ALCOHOL CONSUMPTION; ALCOHOL WITHDRAWAL; ALCOHOLISM; ARTICLE; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DRUG COST; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION; ADULT; COMPARATIVE STUDY; HOSPITALIZATION; MIDDLE AGED; PSYCHOLOGIC TEST;

ADULT; ALCOHOLISM; FEMALE; FRUCTOSE; HUMANS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; NEUROPROTECTIVE AGENTS; PSYCHOLOGICAL TESTS; SEVERITY OF ILLNESS INDEX;

EID: 54749152469     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/j.1530-0277.2008.00680.x     Document Type: Article

References (52)

1. Allen JP, Litten RZ (2001a) The role of laboratory tests in alcoholism treatment. J Subst Abuse Treat 20:81-85.
2. Allen JP, Litten RZ, Strid N, Sillanaukee P (2001b) The role of biomarkers in alcoholism medication trials. Alcohol Clin Exp Res 25:1119-1125.
3. Angehagen M, Rönnbäck L, Hansson E, Ben-Menachem E (2005) Topiramate reduces AMPA - induced Ca (2 +) transients and inhibits GluR1 subunits phosphorylation in astrocytes from primary cultures. J Neurochem 94:1124-1130.
4. Anton RF, Moak DH, Latham P (1995) The obsessive compulsive drinking scale: a self- rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res 19:92-99.
5. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A (2006) COMBINE Study Research Group. Combined pharmacotherapies and behavioral interventions for alcohol dependence - the COMBINE study: a randomized controlled trial. JAMA 295:2003-2017.
6. Arnone D (2005) Review of the use of topiramate for treatment of psychiatric disorders. Ann Gen Psychiatry 4:5.
7. Babor TF, Longabaugh R, Zweben A, Fuller RK, Stout RL, Anton RF, Randall C (1994) Issues in the definition and measurement of drinking outcomes in alcoholism treatment research. J Stud Alcohol 12:101-111.
8. Batel P, Pessione F, Maitre C, Rueff B (1995) Relationship between alcohol and tobacco dependencies among alcoholics who smoke. Addiction 90:977-980.
9. Bobes J, Carreno JE, Gutierrez CE, San Narciso GI, Antuna MJ, Diaz T, Fernandez JJ, Cerceda A, Alvarez CE, Marina P, Garcia-Garcia M (2004) Study of effectiveness of craving control with topiramate in patients with substance dependence disorders. Actas Esp Psiquiatr 32:299-306.
10. Buck KJ (1996) Molecular genetic analysis of the role of GABAergic systems in the behavioral and cellular actions of alcohol. Behav Genet 26:313-323.
11. Carroll KM (1996) Relapse prevention as a psychosocial treatment: a review of controlled clinical trials. Exp Clin Psychopharmacol 4:46-54.
12. Chang PH, Steinberg MB (2001) Alcohol withdrawal. Med Clin North Am 85:1191-1212.
13. Cisler RA, Zweben A (1999) Development of a composite measure for assessing alcohol treatment outcome: operationalization and validation. Alcohol Clin Exp Res 23:263-271.
14. Corrao G, Bagnardi V, Zambon A, Arico S (1999) Exploring the dose-response relationship between alcohol consumption and the risk of several alcohol-related conditions: a meta -analysis. Addiction 94:1551-1573.
15. Daeppen JB, Smith TL, Danko GP, Gordon L, Landi NA, Nurnberger JI Jr, Bucholz KK, Raimo E, Schuckit MA (2000) Clinical correlates of cigarette smoking and nicotine dependence in alcohol-dependent men and women. The Collaborative Study Group on the Genetics of Alcoholism. Alcohol 35:171-175.
16. De Witte P (1996) The role of neurotransmitters in alcohol dependence: Animal research. Alcohol 31(suppl 1):13-16.
17. EuroQoL Group (1990) EuroQoL - a new facility for the measurement of health - related quality of life. Health Policy 16:199-208.
18. Fagerström KO (1978) Measuring degrees of physical dependence to tobacco smoking with reference to individualization of treatment. Addict Behav 3:235-241.
19. Faingold CL, N'Gouemo P, Riaz A (1998) Ethanol and neurotransmitter interactions - from molecular to integrative effects. Prog Neurobiol 55:509-535.
20. Gordis E (1998) The neurobiology of alcohol abuse and alcoholism: building knowledge, creating hope. Drug Alcohol Depend 51:9-11.
21. Hillemacher T, Bayerlein K, Wilhelm J, Frieling H, Thurauf N, Ziegenbein M, Kornhuber J, Bleich S (2006) Nicotine dependence is associated with compulsive alcohol craving. Addiction 101:892-897.
22. Holbrook AM, Crowther R, Lotter A, Cheng C, King D (1999) Meta - analysis of benzodiazepine use in the treatment of acute alcohol withdrawal. CMAJ 160:649-655.
23. Irvin JE, Bowers CA, Dunn ME, Wang MC (1999) Efficacy of relapse prevention: a meta - analytic review. J Consult Clin Psychol 67:563-570.
24. Jaffe AJ, Rounsaville B, Chang G, Schottenfield RS, Meyer RF, O'Malley SS (1996) Naltrexone, relapse prevention and supportive therapy with alcoholics: an analysis of patient treatment matching. J Consult Clin Psychol 64:1044-1063.
25. Janca A, Kastrup M, Katschnig H, López - Ibor JJ, Mezzich JE, Sartorius N (1996) The World Health Organization Short Disability Assessment Schedule (WHO DAS - S): a tool for the assessment of difficulties in selected areas of functioning of patients with mental disorders. Soc Psychiatry Psy-chiatr Epidemiol 31:349-354.
26. John U, Meyer C, Rumpf HJ, Schumann A, Thyrian JR, Hapke U (2003) Strength of the relationship between tobacco smoking, nicotine dependence and the severity of alcohol dependence syndrome criteria in a population-based sample. Alcohol 38:606-612.
27. Johnson BA (2005) Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function. CNS Drugs 19:873-896.
28. Johnson BA, Ait-Daoud N, Akhtar FZ, Jennie S (2004a) Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol - dependent individuals. Arch Gen Psychiatry 61:905-912.
29. Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, Javors MA, Ma JZ (2003) Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 361:1677-1685.
30. Johnson BA, Rosenthal N, Capece JA, Wiegand F, Beyers K, McKay A, Ait-Daoud N, Anton RF, Ciraulo DA, Kranzler HR, Mann K, O'Malley SS, Swift RM. (2007) Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 298:1641-1651.
31. Johnson BA, Swift RM, Ait-Daoud N, DiClemente CC, Javors MA, Malcolm RJ Jr (2004b) Development of novel pharmacotherapies for the treatment of alcohol dependence: focus on antiepileptics. Alcohol Clin Exp Res 28:295-301.
32. Kessler RC, Berglund P, Demler O, Jin R, Walters EE (2005) Lifetime prevalence and ago - of - onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:593-602.
33. Kokkevi A, Hartgers C (1995) European adaptation of a multidimensional assessment instrument for drug and alcohol dependence. Eur Addict Res 1995:1.
34. Koob GF, Roberts AJ, Schulteis G, Parsons LH, Heyser CJ, Hyytia P, Merlo - Pich E, Weiss F (1998) Neurocircuitry targets in ethanol reward and dependence. Alcohol Clin Exp Res 22:3-9.
35. Lingjaerd O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987) The UKU side effect rating scale. Acta Psychiatr Scand 76:1-100.
36. Little HJ (2000) Behavioral mechanisms underlying the link between smoking and drinking. Alcohol Res Health 24:215-224.
37. Loranger AW, Sartorius N, Andreoli P, Berger P, Buchheim SM, Channaba-savanna SM, Coid B, Dahl A, Diekstra RF, Ferguson B (1994) The international personality disorder examination. Arch Gen Psychiatry 51:215-224.
38. Morisky DE, Green LW, Levine DM (1986) Concurrent and predictive validity of a self- reported measure of medication adherence. Med Care 24:67-74.
39. Rehm J, Room R, Monteiro M, Gmel G, Graham K, Rehn T, Sempos CT, Frick U, Jerningan D (2004) Alcohol use, in Comparative Quantification of Health Risks: Global and Regional Burden of Disease Attributable to Selected Major Risk Factors, Vol. 1 (Ezzati M, Lopez AD, Rodgers A, Murray CJL eds), pp 995-1108. World Health Organization, Geneva.
40. Rollnick S, Heather N, Gold R, Hall W (1992) Development of a short 'readiness to change' questionnaire for use in brief, opportunistic interventions among excessive drinkers. Br J Addict 87:743-754.
41. Rubio G, Jiménez - Arriero MA, Ponce G, Palomo T (2001) Naltrexone versus acamprosate: one year follow - up of alcohol dependence treatment. Alcohol 36:419-425.
42. Saitz R, Mayo - Smith MF, Roberts MS (1994) Individualized treatment for alcohol withdrawal. JAMA 272:519-523.
43. Sanchis-Segura C, Borchardt T, Vengeliene V, Zghoul T, Batcheler D, Gass P, Sprengel R, Spanagel R (2006) Involvement of the AMPA receptor GluR-C subunit in alcohol - seeking behavior and relapse. J Neurosci 26:1231-1238.
44. Schaffer A, Naranjo CA (1998) Recommended drug treatment strategies for the alcoholic patient. Drugs 56:571-585.
45. Srisurapanot M, Jarusuraisin N (2005) Naltrexone for the treatment of alcoholism: a meta - analysis of randomized controlled trials. Intern J Neuropsychopharmacol 8:267-280.
46. Stout RL (2003) Methodological and statistical considerations in measuring alcohol treatment effects. Alcohol Clin Exp Res 27:1686-1691.
47. The Combine Study research Group (2003) Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: rationale ans methods. Alcohol Clin Exp Res 27:1107-1122.
48. Vocci FJ, Acri J, Elkashef A (2005) Medication development for addictive disorders: the state of the science. Am J Psychiatry 2005:162.
49. White IR, Altmann DR, Nanchahal K (2002) Alcohol consumption and mortality: modelling risks for men and women at different ages. BMJ 325:191-198.
50. Williams D, McBride AJ (1998) The drug treatment of alcohol withdrawal symptoms: a systematic review. Alcohol 33:103-115.
51. World Health Organization (1992) ICD-10 10th Revision of the International Classification of Diseases. World Health Organization, Madrid.
52. Yoshimoto K, McBride WJ, Lumeng L, Li TK (1992) Ethanol enhances the release of dopamine and serotonin in the nucleus accumbens of HAD and LAD lines of rats. Alcohol Clin Exp Res 16:781-785.